EUVIMEDEUVIMED entdecken
Crossref

Clostridioides difficile infection (CDI): A pan-European multi-center cost and resource utilization study, results from the Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI)

Sebastian M Wingen-Heimann, Kerrie Davies, Virginie F Viprey, Georgina Davis, Mark H Wilcox, Maria J G T Vehreschild, Lise Lurienne, Pierre-Alain Bandinelli, Oliver A Cornely, Tuba Vilken, Sina M Pütz, Jörg Janne Vehreschild und 1 weitere

Clinical Microbiology and Infection · 2023-05 · 29 (5) · 651.e1-651.e8

DOI: 10.1016/j.cmi.2022.12.019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Microbiology and Infection, 2023-05. Verfasst von Sebastian M Wingen-Heimann und 12 weiteren Autor:innen. Beteiligte Einrichtung: University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Cologne, Germany; University of Applie…. Hauptthemen laut MEDLINE: Hospitalization, Clostridium Infections. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Innovative Medicines Initiative, Horizon 2020, European Federation of Pharmaceutical Industries and Associations.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Clostridioides difficile infection (CDI) is one of the leading nosocomial infections worldwide, resulting in a significantly increasing burden on the healthcare systems. However, Pan-European data about cost and resource utilization of CDI treatment do not exist. METHODS: A retrospective analysis within the Combatting Bacterial Resistance in Europe CDI project was conducted based on resource costs for inpatient treatment and productivity costs. Country-specific cost values were converted to EURO referred to 1 January, 2019 values. Differences in price levels for healthcare services among the participating countries were adjusted by using an international approach of the Organisation for Economic Co-operation and Development. As the study focused on patients with recurrent CDI, the observed study population was categorized into (a) patients with CDI but without CDI recurrence (case group), (b) patients with CDI recurrence (recurrence group), and (c) patients without CDI (control group). RESULTS: Overall, 430 hospitalized patients from 12 European countries were included into the analysis between July 2018 and November 2018. Distribution of mean hospital length of stay and mean overall costs per patient between the case group, recurrence group, and control group were as follows: 22 days (95% CI 17-27 days) vs. 55 days (95% CI 17-94 days) vs. 26 days (95% CI 22-31 days; p 0.008) and € 15 242 (95% CI 10 593-19 891) vs. € 52 024 (95% CI 715-103 334) vs. € 21 759 (95% CI 16 484-27 035; p 0.010), respectively. The CDI recurrence rate during the observational period was 18%. Change escalation in CDI medication (OR 3.735) and treatment in an intensive care unit (OR 5.454) were found to be the most important variables associated with increased overall costs of patients with CDI. CONCLUSIONS: Treatment of patients with recurrent CDI results in a significant burden. Prevention of CDI recurrences should be in focus of daily patient care to identify the most cost-effective treatment strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HospitalizationClostridium InfectionsHumansRetrospective StudiesHealth Care CostsEuropeRecurrence

Stichwörter der Autor:innen

Burden of Clostridioides difficile infection (CDI)CDI recurrenceGuideline-based therapyProductivity costsProlonged hospitalizationResource costs for inpatient treatment

Autor:innen und Institutionen

  • University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Cologne, Germany; University of Applied Sciences for Economics and Management (FOM), Cologne, Germany; Unive…
  • Healthcare Associated Infections Research Group, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, United Kingdom; The European Study Group for C. difficile, European Society of Clinical Microbiology an…
  • Healthcare Associated Infections Research Group, Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom.
  • Healthcare Associated Infections Research Group, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, United Kingdom.
  • Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Da Volterra, Paris, France.

Förderung

  • Innovative Medicines Initiative
  • Horizon 2020
  • European Federation of Pharmaceutical Industries and Associations

Zitieren

APA

Wingen-Heimann, S. M., Davies, K., Viprey, V. F., Davis, G., Wilcox, M. H., Vehreschild, M. J. G. T., Lurienne, L., Bandinelli, P. A., Cornely, O. A., Vilken, T., Pütz, S. M., Vehreschild, J. J., & COMBACTE-CDI consortium (2023). Clostridioides difficile infection (CDI): A pan-European multi-center cost and resource utilization study, results from the Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI). Clinical Microbiology and Infection, 29(5), 651.e1-651.e8. https://doi.org/10.1016/j.cmi.2022.12.019

Vancouver

Wingen-Heimann SM, Davies K, Viprey VF, Davis G, Wilcox MH, Vehreschild MJGT, et al. Clostridioides difficile infection (CDI): A pan-European multi-center cost and resource utilization study, results from the Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI). Clinical Microbiology and Infection. 2023;29(5):651.e1-651.e8. doi:10.1016/j.cmi.2022.12.019

BibTeX
@article{WingenHeimann2023,
  author = {Wingen-Heimann, Sebastian M and Davies, Kerrie and Viprey, Virginie F and Davis, Georgina and Wilcox, Mark H and Vehreschild, Maria J G T and Lurienne, Lise and Bandinelli, Pierre-Alain and Cornely, Oliver A and Vilken, Tuba and Pütz, Sina M and Vehreschild, Jörg Janne and COMBACTE-CDI consortium, COMBACTE-CDI consortium},
  title = {Clostridioides difficile infection (CDI): A pan-European multi-center cost and resource utilization study, results from the Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI)},
  journal = {Clinical Microbiology and Infection},
  year = {2023},
  volume = {29},
  number = {5},
  pages = {651.e1--651.e8},
  doi = {10.1016/j.cmi.2022.12.019}
}
Kostenlos starten →